Fixed dose combination dextromethorphan-bupropion: A hope for treatment resistant depression (TRD).
Indian journal of psychiatry June 1, 2025 Ranjan Das, Rajarshi Chakravarty, Varaha V Gantait et al. 4 citations
About 30% of people with depression do not respond to two adequate trials of antidepressants from different classes, a condition known as treatment-resistant depression (TRD). Existing options for TRD include olanzapine-fluoxetine, rTMS, intravenous ketamine, and electroconvulsive therapy. The newer antidepressant dextromethorphan-bupropion has been found effective, fast-acting, and well tolerated for depression. In three cases of TRD, this medication, used alone or in combination, produced satisfactory improvement within two weeks.